KevinJamesHorganMD
Gastroenterology • Los Angeles, CAMember, Digestive Diseases/Gastroenterology, UCLA School of Medicine
Dr. Horgan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 Medical 530 420 120 Plz
# 365
Los Angeles, CA 90095Phone+1 310-794-9718Fax+1 310-301-8751
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gastroenterology, 1991 - 1993
Johns Hopkins UniversityResidency, Internal Medicine, 1985 - 1988
University College Cork Faculty of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1991 - 2020
MD State Medical License 1990 - 1992
Clinical Trials
- A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer Start of enrollment: 2009 Dec 01
Publications & Presentations
PubMed
- 276 citationsRoles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression,...Yoji Shimizu, Gijs A. Van Seventer, Kevin J. Horgan, Stephen Shaw
Immunological Reviews. 1990-04-01 - 1831 citationsCardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trialRobert S. Bresalier, Robert S. Sandler, Hui Quan, James A. Bolognese, Bettina Oxenius
The New England Journal of Medicine. 2005-03-17 - 439 citationsAddition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a...Sergio Poli‐Bigelli, Jose Rodrigues‐Pereira, Alexandra D. Carides, Guoguang Julie Ma, Krista Eldridge
Cancer. 2003-06-15
Press Mentions
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative ColitisJanuary 3rd, 2019- Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational UpdatesNovember 8th, 2018
- Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical OfficerOctober 22nd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
